Clinical Trial

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-07-19; most recent amendment 2026-04-01.
Status change: Not Yet Recruiting → Recruiting 2024-08-05
Status change: Withheld → Not Yet Recruiting 2024-07-29
Trial Details
NCT Number NCT06517888
Lead Sponsor Akouos, Inc.
Collaborators: Eli Lilly and Company
Conditions Vestibular Schwannoma
Enrollment 27 participants
Start Date 2025-01-17
Primary Completion 2029-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-06